Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer

21 Jun 2022

Abstract excerpt

Decoy technology is a versatile and specific DNA oligonucleotide-based targeting strategy of pathogenic transcription factors (TFs). Chemical modifications of linear decoy oligonucleotides have been made to decrease nuclease sensitivity because of the presence of free ends but at the cost of new limitations that affect their use as therapeutic drugs. Although a short DNA minicircle is a phosphodiester nucleic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to MicroRNA in disease regulation
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35847174
DOI: 10.1016/j.omtn.2022.06.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancerPMID 35847174Read ↗

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription FactorSemantic proximity Read ↗

First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer TherapySemantic proximity Read ↗

Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers MatterSemantic proximity Read ↗

Targeting Stat3 in cancer therapySemantic proximity Read ↗

Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancerSemantic proximity Read ↗

A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell lineSemantic proximity Read ↗

Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3Semantic proximity Read ↗

Decoy-PROTAC for specific degradation of “Undruggable” STAT3 transcription factorSemantic proximity Read ↗

STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genesSemantic proximity Read ↗

Targeting STAT3 in Cancer with Nucleotide TherapeuticsSemantic proximity Read ↗

Efficacy of DNA Intercalator-Conjugated Triplex-Forming Oligonucleotide for Anticancer TherapySemantic proximity Read ↗

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.